The ATP-gated P2X1 ion channel contributes to the severity of antibody-mediated Transfusion-Related Acute Lung Injury in mice by El Mdawar, M-B et al.
1Scientific RepoRts |          (2019) 9:5159  | https://doi.org/10.1038/s41598-019-41742-9
www.nature.com/scientificreports
The ATP-gated P2X1 ion channel 
contributes to the severity of 
antibody-mediated transfusion-
Related Acute Lung Injury in mice
Marie-Belle el Mdawar, Blandine Maître, stéphanie Magnenat, Christian Gachet, 
Béatrice Hechler & Henri de la salle
the biological responses that control the development of transfusion-Related Acute Lung Injury 
(TRALI), a serious post-transfusion respiratory syndrome, still need to be clarified. Since extracellular 
nucleotides and their P2 receptors participate in inflammatory processes as well as in cellular responses 
to stress, we investigated the role of the ATP-gated P2X1 cation channel in antibody-mediated TRALI. 
The effects of NF449, a selective P2X1 receptor (P2RX1) antagonist, were analyzed in a mouse two-
hit model of TRALI. Mice were primed with lipopolysaccharide (LPS) and 24 h later challenged by 
administrating an anti-MHC I antibody. The selective P2RX1 antagonist NF449 was administrated 
before the administration of LPS and/or the anti-MHC I antibody. When given before antibody 
administration, NF449 improved survival while maximal protection was achieved when NF449 
was also administrated before the sensitization step. Under this later condition, protein contents 
in bronchoalveolar lavages were dramatically reduced. Cell depletion experiments indicated that 
monocytes/macrophages, but not neutrophils, contribute to this effect. In addition, the reduced lung 
periarteriolar interstitial edemas in NF449-treated mice suggested that P2RX1 from arteriolar smooth 
muscle cells could represent a target of NF449. Accordingly, inhibition of TRPC6, another cation channel 
expressed by smooth muscle cells, also reduced TRALI-associated pulmonary interstitial and alveolar 
edemas. These data strongly suggest that cation channels like P2RX1 or TRPC6 participate to TRALI 
pathological responses.
Transfusion-related acute lung injury (TRALI) is defined as a non-cardiogenic pulmonary edema occur-
ring during or within 6 hours of blood transfusion1,2. TRALI is the most prevalent remaining cause of 
transfusion-associated morbidity and mortality3 and there is no satisfactory therapeutic option4. Retrospective 
studies have shown that anti-HLA I, anti-HLA II or anti-HNA allogeneic antibodies present in the transfused 
products can trigger TRALI; the involvement of metabolic triggers released during the storage of platelets and/
or erythrocytes is debated5. An early model of the pathology proposed that two circumstances concur to provoke 
this syndrome6: an inflammatory state of the receiver (first hit) and the transfusion of a blood product contain-
ing allogeneic antibodies from the donor and/or storage-derived metabolites (second hit). A one-hit model has 
also been proposed, postulating that the presence of relatively high amounts of pathogenic triggers could induce 
TRALI in the absence of adverse clinical conditions. Nevertheless, in practice, transfusions are performed to 
compensate a pathological state and epidemiologic analyses indicate that the severity of TRALI is correlated with 
the seriousness of the pre-transfusion disease, supporting the two-hit model5.
Experimentally, TRALI can be provoked within minutes in mice of the H-2d MHC haplotype by injecting the 
anti-MHC I monoclonal antibody (mAb) 34-1-2S. Hematopoietic cells are major effectors of TRALI responses 
provoked by anti-MHC I antibodies, but the diversity of the experimental conditions (one hit versus two hit 
model, amount of injected antibodies, genotype of the animals) have resulted in various conclusions about the 
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contributions of the different blood populations. Cell depletion and/or transfer experiments have indicated that 
neutrophils are either essential7–9 or dispensable10 for lung edema formation. Other cells participate to TRALI 
responses like monocytes and/or macrophages10,11, while they control neutrophil recruitment in the lungs 
through MIP2 secretion11. TRALI develops similarly in wild type and rag2-deficient mice, indicating that lym-
phocytes do not have a major impact9,10. In contrast, in another mouse model, suppressor T cells or Tregs have 
been reported to inhibit TRALI through IL-10-dependent pathway(s)7,12. In addition, platelets play a critical role9 
or are dispensable13 for the early TRALI-associated responses that lead to lung edema formation.
During acute lung injury, a plethora of stimuli can induce the release of the damage associated molecular pat-
tern adenosine 5′-triphosphate (ATP) from various cell types such as endothelial and immune cells, platelets and/
or stressed erythrocytes. Two classes of membrane receptors mediate the effects of ATP, the ligand-gated P2X cat-
ion channels and the G protein-coupled P2Y receptors14,15. They are expressed in various combinations depend-
ing on the cell type, notably by cells participating in vascular homeostasis15–18. ATP receptors positively regulate 
the recruitment and activation of inflammatory cells19 or control vascular parameters such as endothelial barrier 
integrity and hemodynamics17. Among these receptors, the P2X1 receptor (P2RX1) is expressed on numerous 
cell types involved in vascular homeostasis and/or immunity, namely arterial smooth muscle cells (SMCs), neu-
trophils, macrophages and platelets and therefore might control inflammatory processes involved in the patho-
genesis of TRALI. We investigated whether this receptor influences the pathogenesis of TRALI and if so, which 
P2RX1+ cells could be involved and could potentially represent a biological target relevant to TRALI-associated 
pathologic responses.
Materials and Methods
Reagents. LPS (Escherichia coli, serotype 055: B5) was from Sigma-Aldrich. NF449 (4,4′,4″,4″′-(carbonylb-
is(imino-5,1,3-benzenetriylbis(carbonylimino))) tetrakis-benzene-1,3-disulphonic acid, octasodium salt) and 
SAR7334 were provided by Tocris Bioscience. Xylazine (Rompun) and ketamine (Imalgene 1,000) were from 
Bayer and Merial, respectively. Clodronate liposomes (clodronate 5 mg/mL) were purchased from LIPOSOMA. 
The allogeneic anti-mouse MHC class I (H-2Kd/H-2Dd) mAb (clone 34-1-2S, IgG2a) was from e-Biosciences or 
Bio X Cell and FITC-labeled anti-Ly6C (clone AL-21) from BD Biosciences. Rat anti-mouse Ly6G (clone 1A8), 
A700-labeled anti-CD45 (clone 30-F11) and A647-labeled anti-CD11b (clone M1/70) were from Biolegend. Anti-
CCR2 (clone MC-21) was kindly provided by Dr. Matthias Mack (University of Regensburg, Germany)20.
Mice. Experiments were performed using 8 to 10 week-old male BALB/cByJ mice (JAX collection) purchased 
from Charles River Laboratories and used within one week after arrival. The mice were housed in individual ven-
tilated cages of the animal facilities of the EFS-Grand Est (agreement No. E67-482-10). Ethical approval for the 
animal experiments was obtained from the French Ministry of Research, in accordance with the guidelines of the 
Regional Committee for Ethics in Animal Experimentation of Strasbourg (CREMEAS, CEEA-35).
Two-event TRALI model. A previously described two-hit model was used9 with a few modifications. Male 
BALB/cByJ mice (8 to 10 weeks old) were primed with an intraperitoneal injection of LPS (0.1 mg/kg) 24 h before 
being anesthetized (xylazine (20 mg/kg body weight) and ketamine (100 mg/kg body weight)) and challenged 
with an anti-H-2Kd mAb (clone 34-1-2S, 0.5 mg/kg), its isotype control or saline, injected retro-orbitally. The 
mice were maintained at 37 °C and sacrificed 10 min or 2 h after injection of the anti-MHC I mAb. All experi-
ments were performed in a blinded manner.
Drug administration and specific cell depletion. NF449 (10 mg/kg in saline) was delivered i.v. 5 min 
prior to LPS sensitization and again 5 min before anti-MHC I mAb injection. In some experiments, the mice 
received NF449 either before LPS or before the anti-MHC I mAb. SAR7334 (10 mg/kg in saline) was injected 
retro-orbitally into isoflurane (Vetflurane) anesthetized animals, 30 min before TRALI experiments. Anti-Ly6G 
antibody (clone 1A8, 5 mg/kg in saline) was delivered i.v. 24 h prior to LPS. Anti-CCR2 antibody (clone MC-21, 
0.4 mg/kg in saline) was injected i.p. and clodronate liposomes (2 mL/kg) were injected i.v., 18 h after LPS admin-
istration, i.e., 6 h prior to injection of the anti-MHC I mAb.
Leukocyte counts were determined in whole blood collected into EDTA (6 mmol/L) by severing the tail of 
anesthetized mice, using a Scil Vet ABC automatic cell counter (Scil Animal Care Company) set to murine param-
eters. The percentages of peripheral neutrophils and inflammatory monocytes were determined as described in 
Flow cytometry paragraph, the absolute counts of the cells were deduced.
Partial oxygen pressure (pO2). The partial oxygen pressure (pO2) was measured in blood drawn into a 
syringe containing heparin anticoagulant (50 U/mL) from the abdominal aortas of anesthetized mice, 10 min after 
anti-MHC I injection, using a Critical Care Analyser (OMNIS S; Roche Diagnostics).
Protein content of bronchoalveolar lavages (BALs). At 10 min or 2 h after induction of TRALI, a liga-
tion was performed to isolate the left lung (used later for immunohistochemistry), the tracheas of sacrificed mice 
were exposed and cannulated and 1 mL of sterile PBS solution was injected into the right lung. The bronchoalve-
olar lavages (BALs) were centrifuged at 13,000 × g for 5 min at 4 °C and the supernatants were stored at −80 °C. 
The protein content of BALs was quantified using a bicinchoninic acid assay (Thermo Fisher Scientific) according 
to the manufacturer’s instructions with bovine serum albumin (BSA) as the standard.
Immunohistochemistry. At the end of the experiments, the left lungs of the mice were removed and fixed 
in 4% paraformaldehyde overnight. The fixed samples were washed in PBS and maintained in 10% and then 20% 
sucrose solutions, each time for 24 h, before being snap-frozen in optimal cutting temperature (OCT) embedding 
medium. Sections (8 μm) were stained with hematoxylin and eosin before histological examination. The areas 
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occupied by edema and by the arterioles were quantified using Image J software on images acquired with a Leica 
DMLB microscope and the ratio was calculated. The investigator was blinded to the various experimental groups.
Flow cytometry. Briefly, after TRALI experiments, lungs were perfused with PBS via the right ventricle 
and an incisure was made in the vena cava as an outlet. Lungs were removed en bloc and minced with a scalpel. 
Minced lungs were placed in PBS with 500 U/mL type IV collagenase and 0.02 mg/mL DNase I and were incu-
bated at 37 °C for 30 min. Digested lungs were passed through a 40 μm filter to obtain single cell suspension. After 
incubation, cells were counted (ADAM Automated Cell Counter, Digital Bio), resuspended in PBS-1% BSA and 
Fcγ receptors were blocked with FcR blocking reagent (Miltenyi Biotec). Cells were then stained with directly 
conjugated anti-CD45, -CD11b, -CD11c, -CD24, -Gr1, -CD170, -F4/80 and -MHC class II mAbs to determine 
the percentages of neutrophils and inflammatory monocytes, respectively. Cell depletions were controlled by flow 
cytometric analysis of blood cells stained with directly conjugated anti-CD45, -CD115 and -CD11b mAbs, or 
with anti-CD45 and anti-Ly6C mAbs. Flow cytometric data were acquired on a Fortessa-X20 flow cytometer (BD 
Biosciences) and the cell populations were analyzed using BD FACSDiva software. All subsets were gated using 
fluorescence minus one (FMO) analysis.
Statistical analyses. Statistical analyses were performed with GraphPad software (Prism 5.02). Survival 
studies were analyzed using the log-rank test (Figs 1D, 2A,B and 3B) or the χ2 test (Fig. 2B). Other data are 
reported as the mean ± SEM and were analyzed using 1- or 2-way ANOVA followed by a Dunn’s test or a 
Bonferroni post hoc analysis as appropriate. A P-value of <0.05 was considered to be statistically significant.
Results
The P2RX1 receptor antagonist NF449 decreases the severity of experimental TRALI. To 
explore the role of P2RX1, we used an experimental TRALI model consisting of administration of the anti-MHC 
I mAb 34-1-2S (anti-H-2Kd, -H-2Dd, 0.5 mg/kg) in LPS-sensitized H-2d BALB/c mice, taking advantage of the 
availability of the selective P2RX1 antagonist NF44921,22. NF449 displays good selectivity for the P2RX1 with 
respect to other P2 receptor subtypes and potently antagonizes (IC50 = 5.8 ± 2.2 µM) the P2RX1-mediated calcium 
influx induced by α,β-methyleneadenosine 5′-triphosphate (α,βMeATP) in murine platelets22–24.
Figure 1. NF449 protects mice against experimental TRALI at early and late stages. NF449 (10 mg/kg, i.v.) 
was administered prior to LPS injection (0.1 mg/kg, i.p.) and prior to anti-MHC I antibody challenge (0.5 mg/
kg, i.v., +) or negative control (−). The pathogenesis of TRALI was analyzed 10 min after anti-MHC I mAb 
injection (A,B,C) or 2 h later (D). (A) Left panel: analysis of protein concentrations in BALs using a BCA 
assay, mean ± SEM (***p < 0.001). Right panel: pO2 in aortic blood, mean ± SEM (ns p > 0.05, **p < 0.01, 
***p < 0.001). (B) Representative lung sections stained with eosin and hematoxylin showing periarteriolar 
edema. (C) Ratio of the area of vessels and periarteriolar edema to that of vessels, mean ± SEM (*p < 0.05, 
**p < 0.01, ***p < 0.001). (D) Left panel: Kaplan-Meier survival plots for mice treated with NF449 or vehicle 
(saline solution) (n = 20, ***p < 0.0001, log-rank test). Right panel: analysis of protein concentrations in BALs 
using a BCA assay, mean ± SEM (**p < 0.01, ***p < 0.001).
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BALB/c mice were treated with NF449 (10 mg/kg, i.v.) or vehicle (saline) prior to LPS injection (0.1 mg/kg, 
i.p.) and anti-MHC I antibody challenge (0.5 mg/kg, i.v.). Ten minutes later, the features of experimental TRALI, 
such as lung edema and the drop in blood oxygenation, can be measured whereas survival is evaluated within a 
2 h period. Lung edema is evaluated by quantifying the proteins in bronchoalveolar lavages and respiratory dis-
tress by the measure of the partial oxygen pressure (pO2) in aortic blood as previously described13. After 10 min, 
the protein content of BALs was significantly lower in NF449-treated than in saline-treated animals (Fig. 1A, left 
panel). Accordingly, histological analyses of lung tissues revealed larger areas of interstitial periarteriolar edema 
in saline-treated mice as compared to those receiving NF449 (Fig. 1B,C), while no edema was observed in the 
proximity of the post-alveolar microcirculation (Supplementary Fig. 1). Nevertheless, pO2 dropped similarly in 
both groups (Fig. 1A, right panel).
Within the two hours following antibody injection, 56% of the control mice (treated with saline) died, while 
this percentage fell to 16% in mice receiving NF449 (Fig. 1D, left panel). The protein content of BALs was signifi-
cantly increased in saline-treated mice challenged with the anti-MHC I antibody as compared to non-challenged 
mice. On the other hand, treatment with NF449 reduced the protein concentration in BALs by more than 
two-fold (Fig. 1D, right panel). Altogether, these results indicated that in mice, NF449 reduces the disruption of 
the endothelial barrier provoked by antibody-mediated TRALI, which allows better survival.
Figure 2. NF449 needs to be administered before each step of experimental TRALI to provide maximal 
protection. (A) Effect of the administration of NF449 (10 mg/kg, i.v.) before LPS injection only (0.1 mg/kg, i.p.). 
Kaplan-Meier survival plots for mice treated with NF449 or vehicle (saline solution) (n = 30, ns p > 0.05, log-
rank test). (B) Effect of the administration of NF449 (10 mg/kg, i.v.) before anti-MHC I antibody challenge only 
(0.5 mg/kg, i.v.). Kaplan-Meier survival plots for mice treated with NF449 or vehicle (saline solution) (n = 32, ns 
p > 0.05, log-rank test). Statistical analysis of survival at the 2-hour endpoint indicated a significant protective 
effect of NF449 (n = 32, *p = 0.0384, χ2 test).
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NF449 needs to be administered before each step of experimental TRALI to provide maximal 
protection. We then investigated whether NF449 needed to be administered at each step of the two-hit 
experimental TRALI model, i.e., before LPS sensitization and/or before anti-MHC I mAb challenge, to reduce its 
pathology. The survival of the animals that received saline or NF449 prior to LPS sensitization only was similar 
(Fig. 2A). Therefore, administration of NF449 exclusively before LPS sensitization did not improve survival.
In contrast, when NF449 was delivered only before the anti-MHC I antibody challenge, 33% of the mice died 
as compared to 60% of saline-receiving animals (Fig. 2B). Interestingly, whereas the whole survival curves of 
saline- and NF449-treated mice revealed no significant differences, survival at the 120 min endpoint was signif-
icantly improved in those receiving NF449 (n = 32, *p = 0.0384, χ2 test). Thus, treatment with NF449, before 
antibody administration only, improved survival, while maximal reduction of the severity of experimental TRALI 
required administration of NF449 also before the sensitization step.
The protective effect of NF449 does not rely on neutrophils and inflammatory mono-
cytes. Subsequently, we evaluated the contribution of P2RX1+ immunological cells to TRALI, namely neu-
trophils, monocytes and macrophages. Neutrophils can be selectively depleted for at least three days by treatment 
with the anti-Ly6G mAb 1A825. This antibody was administered 24 h before LPS sensitization and flow cytometric 
analyses performed 48 h later, before anti-MHC I injection, confirmed their depletion (Supplementary Fig. 2A). 
The pathology of TRALI at the 10 min time point was similar in 1A8-treated and untreated mice, as assessed 
by the measure of the protein concentration in BALs and the pO2 (Fig. 3A). Immunohistology confirmed that 
neutrophils could not be detected in the lungs of 1A8-treated mice after TRALI, indicating that even residual 
circulating neutrophils had not been recruited (Supplementary Fig. 2B).
We next tested whether NF449 still has a protective effect on survival in neutropenic animals over a 2 h time 
course. In the absence of NF449 treatment, neutrophil depletion did not modify the severity of antibody-mediated 
TRALI in terms of survival at the 2 h endpoint (Fig. 3B, left panel). In contrast, 80% of mice treated with NF449 
survived regardless of the neutrophil count (Fig. 3B, left panel). Accordingly, the protein content of BALs was 
similarly elevated after TRALI in neutropenic and non-neutropenic mice that did not receive NF449, but signifi-
cantly decreased in NF449-treated animals (Fig. 3B, right panel). These results indicated that neutrophils do not 
play a major role in experimental TRALI and hence that other cell types must be responsible for the contribution 
of P2RX1 to TRALI.
We then used clodronate liposomes, which eliminate all types of monocytes and also macrophages. To 
allow inflammation to proceed, the liposomes were delivered 18 h after LPS, i.e., 6 h before anti-MHC I mAb 
injection. Flow cytometric analyses confirmed that this procedure depleted tissue macrophages and peripheral 
monocytes (Supplementary Fig. 3A,B). Under these conditions, antibody-mediated TRALI was totally abol-
ished. Indeed, 10 min after anti-MHC I administration, the protein content of BALs was dramatically reduced 
in clodronate-treated mice as compared to control animals (Fig. 4A, left panel) and no interstitial edema was 
observed on histological preparations (Fig. 4A, right panel).
We then attempted to evaluate the specific contribution of monocytes. Monocytes can be divided into two 
main subtypes, the patrolling and the inflammatory monocytes. The former weakly express Ly6C and are CCR2−, 
whereas the latter are Ly6C+ and CCR2+ and represent the major subclass of blood monocytes (80% of mono-
cytes in BALB/c mice). This pattern allows the depletion of inflammatory monocytes, whereas there is no availa-
ble treatment to specifically deplete patrolling monocytes in BALB/c mice. Administration of the anti-CCR2 mAb 
MC-21, 18 h after LPS treatment, i.e., after the maximum concentration of inflammatory cytokines in the blood 
had been reached26, resulted in the depletion of inflammatory monocytes (Supplementary Fig. 2C), in accordance 
with previous studies20. This cell specific depletion did not modify the development of TRALI triggered 6 h later, 
Figure 3. Neutrophil depletion does not prevent the development of TRALI, whereas treatment with NF449 
does. (A) The mAb 1A8 (5 mg/kg, i.v.), or rIgG2ak, was administered 24 h before LPS (0.1 mg/kg, i.p.) and the 
pathogenesis of TRALI was analyzed 10 min after anti-MHC I mAb challenge (0.5 mg/kg, i.v., +) or negative 
control antibody (−). Left panel: protein concentrations in BALs, mean ± SEM (**p < 0.01, ns p > 0.05). 
Right panel: pO2 in aortic blood, mean ± SEM (*p < 0.05, ns p > 0.05). (B) The mAb 1A8, or rIgG2ak, was 
injected 24 h before LPS, NF449 (10 mg/kg, i.v.) was delivered prior to LPS injection and prior to anti-MHC 
I mAb challenge (0.5 mg/kg, i.v.) and the pathogenesis of TRALI was analyzed 2 h later. Left panel: Kaplan-
Meier survival plots for mice treated or not with 1A8 and/or NF449 (***p < 0.001, log-rank test, −NF449 vs 
+NF449). Right panel: protein concentrations in BALs, mean ± SEM (ns p > 0.05, *p < 0.05, **p < 0.01).
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as assessed by measurement of the protein content of BALs (Fig. 4B, left panel) and the aortic pO2 (Fig. 4B, right 
panel). We could therefore conclude that inflammatory monocytes are dispensable for the initiation of experi-
mental antibody-mediated TRALI.
Altogether, these findings strongly indicate that activation of patrolling monocytes and/or macrophages trig-
gers the pathology of TRALI and that their P2RX1 could contribute to TRALI.
The protective effect of NF449 is consistent with a contribution from P2RX1 expressed on lung 
periarteriolar smooth muscle cells (SMCs). The development of pulmonary periarteriolar edemas dur-
ing TRALI early biological responses might be driven in part by the pulmonary arterial pressure. The blood pres-
sure in the lung pre-capillary arterioles is controlled by SMCs. Contraction of these cells is positively regulated by 
P2RX1 present on their surface27 and their deficiency prevents the development of pulmonary arterial hyperten-
sion27. Thus, the reduced edema areas in NF449-treated mice could be due to the inhibition of periarteriolar SMC 
contraction. Interestingly, inhibition of another cation channel, the TRPC6 calcium channel, which is expressed 
by pulmonary SMCs, also inhibits pulmonary arterial hypertension and the associated edema during acute lung 
injury28.
We therefore tested the effects on TRALI of SAR7334, a specific inhibitor of TRPC6. SAR7334 was admin-
istered i.v. 30 min before the anti-MHC I mAb and TRALI responses were analyzed 10 min later. Remarkably, 
the quantity of proteins in BALs was reduced in animals receiving the inhibitor (Fig. 5). Histological 
Figure 4. Monocyte/macrophage depletion, but not inflammatory monocyte depletion, prevents the 
development of TRALI. (A) Clodronate liposomes (2 mL/kg, i.v.), or saline, were injected 6 h before the anti-
MHC I mAb (0.5 mg/kg, i.v.). Left panel: protein concentrations in BALs, mean ± SEM (**p < 0.01, *p < 0.05). 
Right panel: ratio of the area of interstitial edema to the vessel area, mean ± SEM (**p < 0.01, *p < 0.05). 
(B) MC-21 (0.4 mg/kg, i.p.), or rIgG2bκ, was injected 6 h before anti-MHC I mAb challenge (0.5 mg/kg, i.v.). 
Left panel: protein concentrations in BALs and right panel, pO2 in aortic blood, mean ± SEM (**p < 0.01, ns 
p > 0.05).
Figure 5. The TRPC6 inhibitor SAR7334 decreases the extent of lung edema. NF449 (10 mg/kg, i.v.) was 
administered 5 min prior to LPS injection (0.1 mg/kg, i.p.) and 5 min prior to anti-MHC I antibody challenge 
(0.5 mg/kg, i.v., +) or negative control (−). SAR7334 (10 mg/kg, i.v.) was administered 30 min prior to anti-
MHC I antibody challenge. Protein concentrations in BALs, mean ± SEM (*p < 0.05, **p < 0.01).
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analyses of the lungs revealed that the extent of periarteriolar edema was diminished after SAR7334 treatment 
(Supplementary Fig. 4). Thus, inhibition of the TRPC6 calcium channel expressed by SMCs reduced the forma-
tion of TRALI-associated lung edema. Combined administration of NF449 and SAR7334 did not however further 
inhibit TRALI-associated lung edema (Fig. 5). These findings strongly suggest that the P2RX1 present on lung 
periarteriolar SMCs could also contribute to the protective effect of NF449.
Discussion
Our present study shows that NF449 reduces the severity of TRALI in mice, indicating a major contribution of the 
P2X1 receptor. Maximal reduction of the experimental TRALI features required treatment with NF449 before the 
sensitization step with LPS and before administration of the anti-MHC I mAb. Of note, NF449 treatment before 
injection of the anti-MHC I mAb only, also resulted in a significant improvement in the survival of the animals.
P2RX1 appeared to control different mechanisms at each step of the two-hit model. LPS responsive cells, 
namely monocytes or macrophages, which express P2RX129, were most likely the primary targets of NF449 in the 
first hit, although the role of P2RX1 on these cells during LPS sensitization remains to be clarified. In the second 
step, the protective effect of NF449 could be related to all cell types expressing the P2RX1 and participating in vas-
cular homeostasis. Endothelial cells (ECs) and platelets were not considered, since ECs do not express P2RX130, 
while platelets are dispensable for the initiation of TRALI13. We first explored the role of neutrophils since P2RX1 
has been shown to control neutrophil responses by amplifying chemotactic signals31,32. Here, their immunodeple-
tion did not modify the features of experimental TRALI at the 10 min or 2 h time points.
This absence of a major role of neutrophils may appear to be in conflict with the accepted view of their impor-
tance in TRALI. However, in the literature, part of the evidence supporting the contribution of neutrophils to 
TRALI responses is indirect. Firstly, in man, post mortem histological analyses have shown that TRALI is accom-
panied by the recruitment of neutrophils to the lungs, but these observations cannot indicate whether this neu-
trophil recruitment is the result or the cause of TRALI initiation33. Anti-HLA class I antibodies could nevertheless 
induce TRALI in a neutropenic receiver (less than 0.1 109 cells/L)34. Secondly, in animal models, neutrophils are 
ideal candidate cells based on their recruitment to the lungs and their ability to produce damaging reactive oxygen 
species in vitro, while conditions inhibiting this production protect the animals from developing TRALI11,35–39.
Direct evidence for the requirement for neutrophils in antibody-mediated TRALI exists, but can be debated. 
It is based on in vivo studies using transfer of isolated bone marrow neutrophils8, which may not be represent-
ative of circulating neutrophils since it is technically difficult to isolate these cells in a resting state, or on cell 
depletion in animals followed by intratracheal instead of intraperitoneal administration of LPS9, which produces 
fundamentally different inflammatory conditions. Indeed, intratracheal administration of LPS leads to neutro-
phil recruitment to the alveoli, whereas intraperitoneal injection of low doses of LPS, as in our work, does not. A 
second team reported that neutrophil depletion blocked lung edema formation7, while a third failed to observe 
any protective effect10. It is difficult to compare our observations with those of these two groups, since the exper-
imental conditions were very different: (i) LPS sensitization in our study versus no sensitization in the two others 
(two-hit versus one-hit model), (ii) different doses of anti-MHC I antibody (0.6 mg/kg in our study versus 5 to 
50 mg/kg), (iii) variable breeding conditions (breeder or animal facility environment) and (iv) different genetic 
backgrounds (BALB/cByJ, BALB/cAnNCrl, BALB/cAnNTac). Notably, with respect to the last two points, BALB/
cByJ and BALB/cAnNCrl mice have been reported to display a different susceptibility to Theiler’s murine enceph-
alomyelitis virus-induced demyelinating disease40, and the commensal microbiota may affect TRALI responses41. 
Nonetheless, we do not exclude that neutrophils could participate in later TRALI responses such as extravasation, 
which requires P2RX1 activity32.
We showed that clodronate liposomes, which eliminate monocytes, macrophages and dendritic cells (DCs), 
protected mice from TRALI. On the other hand, immunodepletion of CCR2+ inflammatory monocytes did not 
influence the development of TRALI, indicating that inflammatory monocytes are not key players in this syn-
drome. How and which of these cells contribute positively to TRALI remains to be elucidated. Distal Kupffer 
cells or splenic macrophages could participate in TRALI, as observed in other ALI models42, or more likely arte-
riolar macrophages43 or dendritic cells44, given the localization of the interstitial lung edema. Administration of 
diphtheria toxin to transgenic animals expressing its receptor on CD11c+ cells, which include DCs, exacerbates 
TRALI-associated lung damage7. However, this experimental set-up can lead to neutrophilia45, which could rep-
resent a confounding effect in this neutrophil-dependent TRALI model. Thus, complementary experiments will 
be required to clarify the role of DCs, at least in our experimental model.
Remarkably, interstitial lung edema was observed in the pre-microcapillary arteriolar spaces but not in the 
post-alveolar circulation. This localization is consistent with the observation that ALI begins with periarteri-
olar edema which, after exceeding a threshold, floods into the alveoli46. Accordingly, real time analyses of the 
development of lung edema in pigs47 or in man have shown that the extravascular lung water volume increases 
before a defect in blood oxygenation is ascertained48. These facts strongly suggest that the arteriolar tissue is 
the primary site of the edematous process during anti-MHC I-induced TRALI. The reduced lung periarteriolar 
interstitial edemas in NF449-treated mice suggested that P2RX1+ vascular SMCs could participate in the for-
mation of interstitial lung edema by promoting arteriolar vasoconstriction and thereby a transient increase in 
pulmonary blood pressure, which would favor plasma leakage46. Stimulation of these cells induces vasoconstric-
tion in a P2RX1-dependent manner, resulting in pulmonary arterial hypertension, which is in part responsible 
for edema formation27. We note that in a rat model of TRALI, transfusion of the plasma from aged erythrocyte 
concentrates was accompanied by an increase in pulmonary arterial blood pressure6. Accordingly, in two cases of 
human TRALI observed after the transfusion of blood products containing anti-HLA class I antibodies, a rise in 
pulmonary arterial tension was detected before the onset of hypoxemia and acute respiratory distress49,50. TRPC6 
is another calcium channel expressed by SMCs, which positively controls vasoconstriction, pulmonary arterial 
hypertension and edema formation28,51. Remarkably, we showed that the TRPC6 inhibitor SAR7334 also reduced 
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the accumulation of proteins in BALs and the extent of the periarteriolar edema provoked by TRALI, which could 
represent the first example of a protective effect in vivo of a specific TRPC6 inhibitor28. The expression profiles 
of TRPC6 in the hematopoietic lineage indicate that murine monocytes and macrophages do not significantly 
express this gene (heamosphere.org and immgen.org), while TRPC6 is expressed by ECs. Therefore, we cannot 
formally exclude that inhibition of endothelial TRPC6 also contributes to the protective influence of SAR7334.
Currently, in the case of TRALI, the mainstay of treatment remains general supportive care, including fluid 
resuscitation, oxygenation or mechanical ventilation52. Recent studies have indicated that the administration of 
IL-10 or CRP inhibitors could represent promising therapeutic or prophylactic strategies53. Our findings now 
suggest that targeting cation channels like P2RX1 or TRPC6, by reducing interstitial lung edema, could constitute 
an additional pharmacological approach for TRALI management, given that intensive medical care lasts several 
hours.
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